Antigen presentation by B cells and persistence of antigen-antibody complexes on follicular dendritic cells (FDC) have been implicated in sustaining T cell memory. In this study we have examined the role of B cells and antibody in the generation and maintenance of CD8 + cytotoxic T lymphocyte (CTL) memory. To address this issue we compared CTL responses to lymphocytic choriomeningitis virus (LCMV) in normal (+/+) versus B cell-deficient mice. The CTL response to acute LCMV infection can be broken down into three distinct phases: (a) the initial phase (days 3-8 after infection) of antigen-driven expansion of virus-specific CD8 § T cells and the development ofeffector CTL (i.e., direct ex vivo killers); (b) a phase of death (between days 10 and 30 after infection) during which >95% of the virus-specific CTL die and the direct effector activity subsides; and (c) the phase of long-term memory (after day 30) that is characterized by a stable pool of memory CTL that persist for the life span of the animal. The role of B cells in each of these three phases of the CTL response was analyzed. We found that B cells were not required for the expansion and activation of virus-specific CTL. The kinetics and magnitude of the effector CTL response, as measured by direct killing of infected targets by ex vivo isolated splenocytes, was identical in B cell-deficient and +/+ mice. Also, the expansion of CD8 + T cells was not affected by the absence of B cells and/or antibody; in both groups of mice there was an "~10,000-fold increase in the number of LCMVspecific CTL and a greater than 10-fold increase in the total number of activated (CD44hi) CD8 + T cells during the first week after virus infection. Although no differences were seen during the "expansion" phase, we found that the "death" phase was more pronounced in B cell-deficient mice. However, this increased cell death was not selective for LCMV-specific CTL, and during this period the total number of CD8 + T cells also dropped substantially more in B cell-deficient mice. As a result of this, the absolute numbers ofLCMV-specific CTL were lower in B cell-deficient mice but the frequencies were comparable in both groups of mice. More significantly, the memory phase of the CTL response was not affected by the absence of B cells and a stable number ofLCMV-specific CTL persisted in B cell-deficient mice for up to 6 too. Upon reinfection, B cell-deficient mice that had resolved an acute LCMV infection were able to make accelerated CTL responses in vivo and eliminated virus more efficiently than naive B cell-deficient mice. Thus, CTL memory, as assessed by frequency of virus-specific CTL or protective immunity, does not decline in the absence of B cells. Taken together, these results show that neither B cells nor antigen-antibody complexes are essential for the maintenance of CD8 + CTL memory.
C
D8 CTL constitute an important defense mechanism against intracellular pathogens (1) (2) (3) (4) . Both effector and memory CTL play critical but distinct roles in antiviral immunity. Effector CTL control infection by killing infected cells and secreting cytokines such as IFN-~/(5-7). Memory CTL play an important role in protective immunity (1) (2) (3) (4) (8) (9) (10) (11) ; they do not prevent infection per se, but limit the severity of infection/disease by making accelerated responses upon reexposllre (8) (9) (10) (11) . Memory CTL are qualitatively distinct from naive CTL and express higher levels of adhesion molecules (8) (9) (10) (11) . Upon reencounter with specific antigen, memory CTL proliferate rapidly, differentiate into effector cells, get to the site of infection, and eliminate infected cells.
Long-term CTL memory is seen in many different antigenic systems and under both natural and experimental situations (8) (9) (10) (11) . For example, mice that have undergone an acute infection with influenza virus, Sendai virus, or lymphocytic choriomeningitis virus (LCMV) 1 exhibit lifelong IAbbreviations used in this paper: FDC, follicular dendritic cell; LCMV, lymphocytic choriomeningitis virus.
were used: R-phycoerythrin-conjugated rat anti-mouse CD4 (RM4-5), biotin-conjugated rat anti-mouse CD8a (53-6.7), FITC-conjugated rat anti-mouse CD44 (IM7) from PharMingen (San Diego, CA), and streptavidin r-phycoerythrin from Caltag Laboratories (South San Francisco, CA). All antibodies were used at concentrations recommended by the manufacturers.
Cytotoxicity Assay. LCMV-specific CTL activity of spleen and LN cells (pooled a,~llary, mesenteric, and inguinal) was measured by a standard 6-h SlCr-release assay on uninfected and LCMV-infected MC57 (H-2 b) targets (26) . To determine CTL recognition of the three major H-2b-restricted LCMV epitopes, MC57 target cells were coated with selected LCMV peptides at a concentration of 2 p~g/ml for 1 h at 37~ Effector cells were then added to prepared targets. Peptides were a gift from Cytel (San Diego, CA).
In kitro Depletion of CD8 + Cells. Spleen cells were treated with anti-Ly 2.2 mAb (anti-CDS) purchased in the form of ascites fluid plus rabbit complement (low tox M; both from Cedarlane Laboratories Ltd., Hornby, ON, Canada) or complement alone. Antibody and complement were used at concentrations specified by the manufacturer. After depletion, cells were enumerated and used as effectors in the cytotoxicity assays.
Antibody Titrations. LCMV-specific antibody in serum was measured by a solid-phase ELISA as previously described (26) .
Determination qf the LCMV-spedfic CTLp Frequency. Spleen cells from LCMV-immunized mice were cultured in graded doses in 96-well flat bottom plates (12 wells per dose). 8 • 10 s syngeneic feeder spleen cells from uninfected mice and 2 • 10 s syngeneic stimulator spleen cells from LCMV carrier mice were irradiated (1,200 rad) and added to each well. Recombinant human IL-2 from Escherichia coli (specific activity 18 • 106 IU mg -~ (Cetus Corp., Emeryville, CA) was added at a final concentration of 50 U m1-1. After 8 d, the contents from each well were split to test CTL activity against LCMV-infected and Uninfected MC57 targets in a 6-h SlCr-release assay.
Results

Kinetics of the CD8 + CTL Effector Response in B Ceii-deftcient Mice.
To determine whether B cells play a role during induction of the primary CTL response, we compared the kinetics of the CTL effector response in B cell-deficient and age-matched C57BL/6 (+/+) mice during an acute LCMV. Mice were infected with 2 • 10 s i.p. PFU of LCMV Armstrong, and direct ex vivo cytotoxicity in the spleens was measured at various times after infection (Table 1) .
On day 3 of infection, the majority of the cytotoxic response in the spleens was nonspecific, with lysis of both LCMV-infected and uninfected target cells. By day 5, LCMV-specific CTL activity was detectable in both the B cell-deficient and +/+ mice. Although there was still some lysis of uninfected target cells, there was less than that seen at day 3. Previous work has shown that the early nonspecific cytotoxic activity after LCMV infection is due to natural killer cells (28) .
The magnitude of the CTL response increased dramatically by day 8 of infection, when spleen cells from both B cell-deficient and +/+ mice demonstrated high specific killing of LCMV-infected targets. Results from two separate experiments showed that the magnitude of the primary CTL effector response in the spleens of -/-mice was corn- 
CD8 + T Cell Expansion and Activation.
For further assessment of the CD8 + T cell response in B cell-deficient mice, we quantitated CD8 expansion and activation after LCMV infection. Six infected and six uninfected mice were evaluated per group. At baseline, uninfected B ceil-deficient mice had significantly smaller spleens than uninfected, age-matched +/+ mice. Spleens from -/-mice were on average sixfold smaller than spleens of +/+ mice, and in addition to lacking B ceils, also contained fewer CD4 + and CD8 + T cells. In -/-mice, the average number ofCD4 + T ceils was 5.5 • 10 6 -~ 1.2 X 10 6 SD versus 1.8 • 10 7 ---+ 4.6 • 106 SD in +/+ mice. The average number of CD8 § T cells was 4.0 X 10 6 + 1.2 • 10 6 SD in --/-mice versus 9.7 X 106 __+ 3.2 X 10 6 SD in +/+ mice. Despite the difference in total numbers, CD8 § spleen cells from B celldeficient and +/+ mice showed a similar degree of expansion in response to LCMV infection. B cell-deficient mice had a 10-fold increase in the number of CD8 § spleen cells by day 8, versus a ninefold increase in +/+ mice.
To assess CD8 activation, cells were double stained for CD8 and CD44, an adhesion molecule whose expression goes up in activated T ceils (8) (9) (10) (11) . Representative FACS | analyses of the spleen and blood from B cell-deficient and +/+ mice are shown in Fig. 1 . Comparison of uninfected and day 8-infected mice illustrates the tremendous increase in the overall percentage of CD8 § cells and the percentage of CD8 § cells expressing the activated (CD44hi) phenotype. The total number of activated CD8 + cells in the spleens increased 20-fold in -/-mice and 10-fold in +/+ mice. Whereas the number of activated CD8 + ceils increased dramatically after infection, the number of resting CD8 + ceils remained relatively unchanged in both groups. This resulted in a large increase in the ratio of activated versus rest- . In uninfected B cell-deficient mice, the ratio of activated to resting CD8 + spleen cells ranged from 0.5 to 0.6. By day 8 after infection, the ratio of activated to resting CD8 + cells had increased an average of 20-fold, and now ranged from 5 to 17. In uninfected +/+ mice, the ratio of activated to resting CD8 + spleen ceils ranged from 0.6 to 1.2. After infection, the ratio ranged from 9 to 25, a 15-fold average increase. These results demonstrated that CD8 + cells in B celldeficient and +/+ mice show a similar degree of expansion and activation after LCMV infection, with a 9-10-fold increase in CD8 numbers and a 15-20-fold increase in the ratio of activated to resting CD8 + cells.
B Cell-deficient Mice Clear an Acute LCMV Infection.
To evaluate the kinetics of viral clearance in B cell-deficient mice, we measured levels of infectious virus in various tissues on days 5 and 8 after LCMV Armstrong infection (Table 3) . On day 5 of infection, infectious virus could be found in the serum, liver, lung, and spleen of both B celldeficient and +/+ mice. Levels of infectious virus were slightly higher in the B cell-deficient mice at day 5, but by day 8, there was no detectable infectious virus in the serum, brain, kidney, liver, lung, or spleens of both the B celldeficient and +/+ mice. The difference in viral titers at day 5 may be related to either the lack of B cells and/or antibody, or to the lower number of CD8 + cells in B celldeficient mice. Overall, however, the kinetics of viral clearance in the B cell-deficient mice follows a similar pattern to that seen in +/+ mice. cient and +/+ mice showed a significant increase in the percentage of CD8 + cells in the spleen and blood after infection, with a tremendous shift in the percentage of cells expressing the activated CD44hi phenotype. X-and Y-axes are in logm fluorescence. Numbers indicate percentage of cells in each quadrant. (The total number of CD8 + T ceils in the spleens of uninfected -/-mice was about twofold less than in +/+ mice, although CD8 percentages were higher in -/-mice because of the absence of B cells). This variation, however, showed no specific trend over time, illustrating that in B cell-deficient and +/+ mice, the CTLp frequencies are being maintained at relatively the same rate. At day 8 after infection, the total number of CTLp per spleen was approximately threefold higher in + / + mice compared with B cell-deficient mice. By day 16, both groups showed a rapid decrease in CTLp numbers and then a more gradual decline until day 50. During this time, when apoptotic T cell death occurred, B cell-deficient mice showed a greater decline in CTLp numbers compared with +/+ mice. B cell--deficient mice had over a 60-fold decrease in LCMV-specific CTLp cells compared with a 13-fold decrease in +/+ mice. From day 80 and beyond, the total number of CTLp cells remained lower in the B cell-deficient mice compared with +/+ mice. Although there was some variation in the total CTLp numbers during this time, both groups then maintained a relatively stable population ofLCMV-specific CTL for up to 6 mo after infection. Fig. 3 B shows the number of activated CD8 + spleen cells (CD44hi) in B cell-deficient and +/+ mice from days 3 to 170 after infection. Uninfected B cell-deficient mice had approximately half the number of CD8 + T cells as the uninfected +/+ mice (with both CD44hi and CD441o cells being two-to threefold lower). By day 8 after LCMV infection, the number of activated CD8 + cells in both -/-and +/+ mice were nearly equal (less than 1.5-fold difference). Numbers of activated CD8+cells began to decrease thereafter, with -/-mice showing a greater drop compared with +/+ mice. From days 8 to 50, B cell-deficient mice had a 23-fold drop in activated CD8 + cells versus a sevenfold drop in +/+ mice. Although B cell-deficient mice showed greater cell loss during the "death" phase, the number of activated CD8 + cells stabilized from day 50 and beyond (in the maintenance phase). Numbers of activated CD8 + cells then remained two-to fivefold lower in B celldeficient mice compared with +/+ mice, returning close to preinfection levels for each group. Fig. 3 C shows that in contrast to the changes seen in the CD44hi population, the number of CD8 + CD441o cells remained relatively stable throughout the time period studied. At day 8 after infection, there was less than a twofold increase in the CD8 + CD441o population in both groups and no dramatic drop in CD8 + CD441o cells during the death phase. The absolute number ofCD8 + CD441o cells remained two-to fivefold lower in -/-compared with + / + mice. Thus, in the absence of B cells and/or antibody, there is a higher rate of death of activated CD8 + cells and LCMVspecific CD8 + CTL memory cells after virus infection. The increased cell death results in lower absolute numbers of activated CD8 + cells and LCMV-specific CTLp in -/-compared with +/+ mice. Lower numbers of LCMVspecific CTL in B cell-deficient mice, however, was not due to selective loss of CTL memory cells, since CTLp frequencies in the spleens of-/-mice were comparable with that seen in +/+ mice and remained relatively constant over time.
Long-term Protective Immunity in B Cell-deficient Mice.
LCMV-specific memory CTL are responsible for mediating protective immunity against reinfection (13, 32) . As an in vivo test of CTL memory, previously immunized B celldeficient mice were rechallenged with LCMV Armstrong (-4) B cell-deficient and +/+ mice were infected with LCMV and the LCMV-specific CTLp frequency in the spleens was quantitated by limiting dilution assay. In both groups, CTLp frequencies were maintained at relatively the same rate over time, peaking at day 8, showing a sigmficant decline by day 16, and stabilizing from day 50 and beyond. Expansion of LCMV-specific CTL in the two groups was comparable, with both B celldeficient and +/+ mice demonstrating up to a 10,000-fold increase in the number of LCMV-specific CTL in the spleen by 8 d after infection. During the cell death phase, -/-mice showed a greater decrease in LCMV-specific CTL compared with +/+ mice. Between days 8 and 50, there was a 60-fold drop in -/-mice versus a 13-fold drop in +/+ mice, From day 50 and beyond, both groups maintained a stable population of LCMV-specific CTL, with absolute numbers in -/-mice remaining lower than in +/+ mice. (B) By 8 d after infection, the total number of activated CD8 + T cells increased 20-fold in -/-mice and 10-fold in +/+ mice. During the death phase, -/-mice showed greater loss of activated CD8 + cells. Activated CD8 + cells stabilized during the maintenance phase, returning close to preinfection levels for both groups of mice. (C) In both -/-and +/+ mice, the number of CD8 + CD441o cells remained relatively stable throughout the time period studied, although total numbers in -/-mice were two-to fivefold lower than in +/+ mice. and evaluated for their ability to generate an accelerated CTL response. B cell-deficient mice immunized 2 mo previously were re-chaUenged with 106 PFU of LCMV Armstrong. Naive (previously uninfected) age-matched B celldeficient mice were similarly infected for comparison. Direct ex vivo CTL activity in the spleens was measured at days 3 and 5 after challenge. Previously immunized -/-mice generated an accelerated LCMV-specific CTL response in the spleen, with virus-specific CTL activity evident by day 3 after challenge (Fig. 4 A) . Naive -/-mice showed no measurable LCMV-specific CTL activity at this time. By day 5 after challenge, virus-specific CTL activity increased even further in the previously immunized group, with 65% LCMV-specific target cell lysis at the 50:1 E/T ratio compared with 15% in the naive mice (data not shown).
Levels of infectious virus were measured on day 3 after challenge, In immunized -/-mice, levels of infectious virus ] is shown for the indicated E/T ratios. Previously immunized mice generated an accelerated LCMV-specific CTL effector response by day 3. Naive mice had no LCMu response at this time. (B) Level of infectious virus in the serum and tissues of challenged mice. Naive mice had high levels of infectious virus in the serum and tissues, whereas levels were below detection in previously immunized mice. Thus, B cell-deficient mice were able to generate a LCMV-specific CTL memory response in vivo al~er viral challenge that was capable of quickly controlling viral spread. Data represent the average of two mice per group. Lines on bar graph indicate range for each group.
in the serum, liver, lung, LN, or spleen, were below detection, whereas naive -/-mice had high levels of infectious virus in both serum and tissues at this time (Fig. 4 B) . Previously immunized +/+ mice also had no detectable infectious virus in the serum and tissues, whereas naive +/+ mice had high levels of infectious virus that were comparable with those in the naive -/-mice (data not shown). Thus, previously immunized B cell-deficient mice generated an accelerated CTL response after LCMV Armstrong challenge and quickly controlled viral infection, demonstrafing the presence of CTL memory in vivo.
As a more stringent in vivo test of CTL memory, challenge experiments were also performed using LCMV variant clone 13 or 28b. Clones 13 and 28b are virulent strains of LCMV that establish persistent infections in naive adult mice characterized by low LCMV-specific CTL responses and high levels of infectious virus in several tissues (26, 27) . B cell-deficient mice immunized between 3 and 6 mo earher with LCMV Armstrong were challenged with 1.5 • 10 6 i.v. PFU of clone 13 or 28b. Naive, age-matched B cell-deficient mice were challenged for comparison. Mice were killed 7 d after infection and direct ex vivo CTL activity in the spleen was measured. CTL activity in immune -/-mice was 10-30-fold higher than in the naive -/-mice (Table 4 ). In addition, there were striking differences in levels of infectious virus in serum and tissues between the two groups. Immune -/-mice had undetectable levels of infectious virus in the serum, brain, liver, lung, and spleen. In sharp contrast, naive -/-mice had very high levels of infectious virus in serum and tissues. Therefore, in two different types of challenge experiments (Annstrong or clones 13/28 b), B cell-deficient mice demonstrated accelerated LCMV-specific CTL memory responses 217l
Asano and Ahmed in vivo that resulted in faster clearance of virus. Thus, CTL-mediated protective immunity does not wane (for at least 6 too) in the absence of B cells or antigen-antibody complexes.
Discussion
In this study we have examined the role of B cells in the generation and maintenance of CD8 + CTL memory. To address this issue we compared CTL responses to LCMV in normal (+/+) versus B cell-deficient mice. The CTL response to acute LCMV infection can be broken down into three distinct phases. (a) The initial phase (days 3-8 after infection) is the phase of antigen-driven expansion of virusspecific CD8 + T cells and the development of effector CTL (i.e., direct ex vivo killers). Most of the viral antigen is cleared during this period. (b) This is followed by a death phase (between days 10 and 30 after infection) during which >95% of the vires-specific CTL die and the number of direct effector cells falls below the level of detection. (c) The third phase is the memory phase (>30 d after infection) and is characterized by a stable pool of memory CTL that persist for the hfe span of the animal. The role of B cells in each of these three phases was analyzed. We found that B cells were not required for the expansion and activation of virus-specific CTL but that the death phase was more pronounced in B cell-deficient mice. A greater proportion of activated CD8 + T cells died in these mice, resulting in lower absolute numbers of virus-specific CTL. However, the memory phase was not affected by the absence of B cells, and a stable number of LCMV-specific memory CTL persisted in B cell-deficient mice. Upon reinfection, the B celldeficient mice that had resolved an acute LCMV infection were able to make accelerated CTL responses in vivo and eliminated virus more efficiently than naive B cell-deficient mice. Taken together, these results show that neither B cells nor antigen-antibody complexes are essential for the maintenance ofCD8 + memory CTL. B cells were not required for the priming and activation of virus-specific CTL responses. The kinetics and magnitude of the effector CTL response, as measured by direct killing of infected targets by ex vivo isolated splenocytes (or LN cells), were almost identical in B cell-deficient and + / + mice. Also, the overall expansion of activated CD8 + T cells was not affected by the absence of B cells; in both +/+ and B cell-deficient mice there was over a 10-fold expansion of activated CD8 + T cells and a "-'10,000-fold increase in the number of LCMV-specific CTL during the first week after virus infection. In addition, we found that virusspecific CTL from B cell-deficient mice recognized the same LCMV epitopes as did CTL from +/+ mice, and the same hierarchy for the three CTL epitopes (NP 396 and GP 33 >GP 276) was seen in both +/+ and -/-mice. Taken together, these results show that B cells are not involved in the priming of virgin CD8 § T cells. In the past, this issue has been somewhat controversial, and in some studies, B cells were found to be essential for T cell priming in vivo (33) (34) (35) (36) . However, several other studies (37) (38) (39) (40) have shown that B cells are unable to activate naive T cells and a recent paper (41) has shown that B cell-deficient mice do not have any defects in making primary CD4 + or CD8 + T cell responses to a variety of antigens. Our finding, along with these other reports, provides strong evidence that B cells are not needed for activating T cells. It is worth pointing out that there was massive expansion and activation of CD8 + T cells in B cell-deficient mice after LCMV infection. These results show that not only are B cells not required for antigen presentation to naive CD8 + T cells, but that B cells play a minimal to no role in providing any necessary signals and/or cytokines for proliferation and differentiation ofCD8 + CTL.
B cell-deficient mice were able to ehminate LCMV and at 8 d after infection there was no detectable infectious virus in any of the tissues tested (spleen, liver, lung, blood, brain, or kidney). This provides formal proof that antibody does not play an essential role in resolving LCMV infection. Earlier studies have shown that CD8 + CTL are the major players in controlling LCMV infection (5, 6, 25, (42) (43) (44) (45) .
Although no differences were seen during the expansion phase of the CTL response between B cell-deficient and +/+ mice, we found that the death phase was more pronounced in -/-mice. Between days 8 and 50 there was a 60-fold drop in the number ofLCMV-specific CTL in B cell-deficient mice compared with a 13-fold drop in +/+ mice. During this period the total number of activated CD8 + T cells also dropped substantially more in the B cell-deficient compared with +/+ mice (23-versus 7-fold). The net result of this increased T cell death was a lower absolute number ofLCMV-specific CTL in B cell-deficient mice (4--20-fold lower). However, it is worth noting that the difference in the frequency of LCMV-specific CTL/spleen cells or CD8 + T cells between the two groups of mice was much less (three-to fourfold), and in some experiments the frequency of virus-specific CTL was the same in +/+ and B celldeficient mice. Why was there more overall T cell death in the absence of B cells? Activated T cells die by apoptosis and there is evidence implicating bothfas and TNF in this process (46, 47) . It is currently not well understood what type of signals and cellular interactions can rescue activated T cells from undergoing apoptosis in vivo, but two recent studies have shown that LPS or TGF-~I can prevent apoptosis of activated T cells (48, 49) . Our results suggest that B cells might deliver signals for rescuing peripheral T cells from death. B cells express a variety of adhesion/costimulatory molecules 037-1, B7-2, CD40, etc.) on their cell surface that are potential candidates for mediating interactions with activated T cells (50) . Some of these interactions may be involved in preventing cell death in peripheral T cells. In this context, it is worth noting that uninfected B cell-deficient mice have lower numbers of both CD4 and CD8 + T cells in their spleens compared with age-and sex-matched +/'+ mice (an average of 5.5 • 106 CD4 + T cells in -/-mice versus 1.8 • 107 in +/+ mice; 4 X 106 CD8 + T cells in -/-mice versus 9.7 • 106 in +/+ mice).
A question of substantial interest was determining if CD8 + T cell memory would persist in the absence of B cells. The results of this study show that CTL memory, as assessed by frequency of virus-specific CTL or protective immunity, does not decline in the absence of B cells. The frequency of LCMV-specific CTL remained relatively constant in B celldeficient mice over a 6-mo period, and these mice were able to make an accelerated CTL response in vivo upon rechallenge with virus. This accelerated CTL response was able to confer protection against a virulent strain (clone 13 or 28b) of LCMV. These LCMV variants cause a persistent infection in naive adult mice but are cleared by immune mice. Ability to control LCMV clone 13 or 28b is a definitive in vivo marker for CTL memory, and immunized B celldeficient mice were able to eliminate this infection efficiently.
It has been proposed that B cells sustain T cell memory by picking up antigen-antibody complexes trapped on FDC, processing this trapped antigen, and then presenting it to T cells (8, 20, 21) . Our results show that this pathway does not play an essential role in sustaining CD8 § T cell memory. Our studies also show that once a stable pool of memory CTL has developed, these cells do not require any signals/help from B cells. Taken together, these results show that memory CD8 + T cells require neither antigen-antibody complexes nor B cells for their survival. It will be of interest to determine if the same rules apply for maintenance of CD4 + T cell memory.
